Director Vincent Milano gets 848 BIOCRYST (BCRX) shares as equity retainer

Rhea-AI Filing Summary

MILANO VINCENT reported acquisition or exercise transactions in this Form 4 filing.

BIOCRYST PHARMACEUTICALS INC director Vincent Milano received 848 shares of Common Stock as a compensation award. The shares were issued at a reference price of $8.75 per share, bringing his directly held total to 92,067 shares after the transaction.

The footnote explains that these shares were issued in lieu of 50% of his quarterly cash Board member retainer of $11,250 and, effective January 23, 2026, in lieu of 50% of the quarterly cash Board Chair retainer of $20,000. This represents routine equity-based director compensation rather than an open-market purchase or sale.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider MILANO VINCENT

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	848	$8.75	$7K

Holdings After Transaction: Common Stock — 92,067 shares (Direct)

Footnotes (1)

1. [object Object]

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

MILANO VINCENT

(Last) (First) (Middle)

4505 EMPEROR BLVD.

SUITE 200

(Street)

DURHAM NC 27703

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
BIOCRYST PHARMACEUTICALS INC [ BCRX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
02/27/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/27/2026		A		848(1)	A	$8.75	92,067	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Shares of Common Stock issued to the reporting person in lieu of 50% of the quarterly cash Board Member retainer of $11,250 and, effective January 23, 2026, in lieu of 50% of the quarterly cash Board Chair retainer of $20,000.

	/s/ Alane P. Barnes, by power of attorney	03/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did BIOCRYST (BCRX) director Vincent Milano report?

Vincent Milano reported an acquisition of 848 shares of BIOCRYST Common Stock. The Form 4 shows this was a stock award, not an open-market trade, and is part of his standard board-related compensation structure.

At what price were the 848 BIOCRYST (BCRX) shares granted to Vincent Milano?

The 848 Common Stock shares were issued at a reference price of $8.75 per share. This price is used for reporting the value of the director’s equity compensation in the Form 4, rather than indicating an open-market purchase.

How many BIOCRYST (BCRX) shares does Vincent Milano hold after this Form 4 transaction?

After the award of 848 shares, Vincent Milano directly holds 92,067 shares of BIOCRYST Common Stock. This updated total reflects his ownership following the routine, stock-based compensation reported in the filing.

Was the BIOCRYST (BCRX) Form 4 for Vincent Milano a market buy or sell?

The Form 4 describes an acquisition coded as a grant or award, not a market trade. Shares were issued as compensation rather than bought or sold on an exchange, indicating routine board-related equity compensation.

Why did Vincent Milano receive BIOCRYST (BCRX) shares instead of cash?

According to the footnote, shares were issued in lieu of 50% of his quarterly cash Board member retainer of $11,250 and, from January 23, 2026, 50% of the $20,000 Board Chair retainer, aligning compensation partly with equity.

What does transaction code “A” mean in the BIOCRYST (BCRX) Form 4 for Vincent Milano?

Transaction code “A” indicates a grant, award, or other acquisition of shares. In this case, the code reflects BIOCRYST issuing Milano 848 Common Stock shares as part of his quarterly board and chair retainers, not an open-market purchase.